Date: 2013-02-15
Type of information: Capital increase
Company: Molmed (Italy)
Investors: Fininvest (Italy) H-Equity (Italy) H-Invest (Italy)
Amount: €4,999,999.00
Funding type: capital increase
Planned used: This share capital increase will allow the injection of new financial resources for the overall operations and it will be used to support Molmed\'s business plan
Others: * On February 28, 2013, MolMed has announced that Fininvest S.p.A. – in accordance with the undertaking announced on 25 January 2013 – has confirmed the subscription of further n. 2,142,480 shares which were unsubscribed upon completion of the offering on the Italian Stock Exchange of the unexercised rights, equal to 17.47% of the total number of the offered shares, for an aggregate amount of € 872,203.61, with payment and delivery of the Shares on 4 March 2013. Therefore, the Share Capital Increase shall end with the full subscription of n. 12,264,576 shares, for an aggregate amount equal to € 4,992,908.92. The new share capital of MolMed shall be equal to € 27,070,992.30, divided into n. 222,806,502 ordinary shares with no par value. * On February 15, 2013, MolMed has announced that the offer with pre-emptive rights to the its hareholders of 12,264,576 newly issued ordinary shares deriving from the share capital increase against payment resolved by the Extraordinary Shareholders’ Meeting held on 21 January 2013, has ended. In the period comprised between 28 January 2013 and 15 February 2013 (included), n. 173,556,648 preemptive subscription rights have been exercised and, therefore, n. 10,110,096 Shares have been subscribed for, equal to 82.43% of the total number of the offered Shares, for an aggregate amount equal to € 4,115,820.11. Upon completion of such period, there are n. 36,985,240 unexercised pre-emptive subscription rights related to the subscription of n. 2,154,480 Shares, equal to 17.57% of the total number of the offered Shares, for an aggregate amount equal to € 877,088.81. The unexercised pre-emptive rights will be offered by the Company on the Italian stock exchange through Banca IMI. On the first day, the Company will offer the entire amount of the pre-emptive subscription rights and in the following days the Company will offer the pre-emptive rights that will still have not been placed. The pre-emptive subscription rights may be used for the subscription of the Shares, having the same characteristics and granting the same rights of the currently outstanding shares, at a price of € 0.4071 per Share of which Euro 0.1215 represents capital and the remainder represents share premium ? at an option ratio of 6 Shares for each 103 existing pre-emptive rights held. The subscription of the Shares shall be carried out through the authorized intermediaries participating to the centralized management system managed by Monte Titoli S.p.A. within and no later than 27 February 2013, under penalty of forfeiture. In addition to the foregoing Fininvest S.p.A., pursuant to the subscription commitment already disclosed to the market, has subscribed the Shares to which it is entitled in accordance with its pre-emptive rights representing 23.94% of the share capital increase; The Shareholders H-Equity S.r.l. and H-Invest S.p.A., following the expression of their availability to fully subscribe their pre-emptive rights, have subscribed the Shares to which they are entitled in accordance with their pre-emptive rights, representing respectively 4.06% and 4.06% of the share capital increase. Fininvest S.p.A. has also irrevocably undertaken to subscribe a number of eventually unsubscribed Shares upon completion of the offering on the Italian stock exchange of the unexercised rights, for an aggregate maximum amount - including the amount of its pre-emptive share - of € 4,600,000.00, under the condition that Fininvest S.p.A. does not exceed the threshold of 30% of the ordinary share capital of the Company or any other relevant threshold which would cause the obligation to launch a mandatory tender offer, pursuant to Article 106 of Legislative Decree nr. 58 of 24 February 1998. The share capital increase is not guaranteed by any banking syndicate. * On 25 January 2013, MolMed has announced that Fininvest has confirmed its participation to this share capital increase. Fininvest will subscribe to the shares to which it is entitled in accordance with its pre-emptive rights, representing 23.94% of the share capital increase. The company would also subscribe to a number of eventually unsubscribed shares upon completion of the offering on the Milan Stock Exchange of the unexercised rights, for an aggregate maximum amount - including the amount of its pre-emptive share - of € 4,600,000.00, under the condition that Fininvest S.p.A. does not exceed the threshold of 30% of the ordinary share capital of Molmed or any other relevant threshold which would cause the obligation to launch a mandat
Therapeutic area: Cancer - Oncology
